TheStreet Downgrades AdaptHealth (NASDAQ:AHCO) to D+

TheStreet cut shares of AdaptHealth (NASDAQ:AHCOGet Rating) from a c- rating to a d+ rating in a report issued on Friday morning, TheStreetRatingsTable reports.

Other analysts have also recently issued reports about the company. Deutsche Bank Aktiengesellschaft lowered their target price on AdaptHealth from $34.00 to $28.00 in a research report on Friday, February 25th. Robert W. Baird lowered their target price on AdaptHealth from $34.00 to $26.00 in a research report on Friday, February 25th. Canaccord Genuity Group lowered their target price on AdaptHealth from $44.00 to $29.00 and set a buy rating on the stock in a research report on Friday, February 25th. Truist Financial lowered their target price on AdaptHealth from $30.00 to $20.00 in a research report on Friday, February 25th. Finally, Zacks Investment Research cut AdaptHealth from a hold rating to a strong sell rating in a research report on Wednesday, April 27th. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of Buy and an average target price of $28.25.

Shares of AdaptHealth stock opened at $12.86 on Friday. The company has a current ratio of 1.34, a quick ratio of 1.09 and a debt-to-equity ratio of 1.06. The business’s 50 day simple moving average is $15.76 and its 200-day simple moving average is $19.63. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of 32.97, a PEG ratio of 0.22 and a beta of 0.47. AdaptHealth has a twelve month low of $12.40 and a twelve month high of $30.33.

AdaptHealth (NASDAQ:AHCOGet Rating) last announced its quarterly earnings results on Thursday, February 24th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.25). The company had revenue of $702.11 million for the quarter, compared to analyst estimates of $693.15 million. AdaptHealth had a return on equity of 7.97% and a net margin of 6.36%. Sell-side analysts predict that AdaptHealth will post 1.4 earnings per share for the current year.

In related news, Director Skyknight Capital Fund Ii, L.P acquired 13,352 shares of the stock in a transaction dated Friday, March 4th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $200,280.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Stephen P. Griggs acquired 32,342 shares of the stock in a transaction dated Thursday, March 3rd. The stock was bought at an average price of $15.44 per share, for a total transaction of $499,360.48. The disclosure for this purchase can be found here. Insiders have purchased a total of 88,180 shares of company stock valued at $1,351,923 in the last three months. 17.30% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dimension Capital Management LLC grew its position in AdaptHealth by 43.1% during the 3rd quarter. Dimension Capital Management LLC now owns 100,790 shares of the company’s stock worth $2,347,000 after acquiring an additional 30,361 shares during the last quarter. OLD Mission Capital LLC acquired a new position in AdaptHealth during the 3rd quarter worth $2,027,000. Swiss National Bank lifted its holdings in AdaptHealth by 35.4% during the 3rd quarter. Swiss National Bank now owns 171,300 shares of the company’s stock worth $3,990,000 after buying an additional 44,800 shares in the last quarter. Emerald Mutual Fund Advisers Trust lifted its holdings in AdaptHealth by 43.0% during the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 363,273 shares of the company’s stock worth $8,886,000 after buying an additional 109,279 shares in the last quarter. Finally, Twinbeech Capital LP acquired a new position in AdaptHealth during the 3rd quarter worth $797,000. Institutional investors and hedge funds own 83.68% of the company’s stock.

AdaptHealth Company Profile (Get Rating)

AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps to patients for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.

Read More

Analyst Recommendations for AdaptHealth (NASDAQ:AHCO)

Receive News & Ratings for AdaptHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AdaptHealth and related companies with MarketBeat.com's FREE daily email newsletter.